RGS2 determines the preventive effects of ARBs against vascular remodeling: toward personalized medicine of anti-hypertensive therapy with ARBs.
Fujio
Yasushi
Y
Department of Clinical Pharmacology and Pharmacogenomics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita City, Osaka 565-0871, Japan. fujio@phs.osaka-u.ac.jp
D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D051379:Mice; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D020710:RGS Proteins / Q000502:physiology*
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D020710:RGS Proteins; C105345:Rgs2 protein, mouse